← Eichor
Condition: Secukinumab Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Secukinumab

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07683065Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Phase N/A · 1 location(s) · Peking Union Medical College · NCT07109765Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Ant
NA · 1 location(s) · University Hospitals Cleveland Medical Center · NCT06399432Real-world Secukinumab Outcomes in Canadian HS Patients
Phase N/A · 15 location(s) · Novartis Pharmaceuticals · NCT07282015Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in
Phase 1 · 8 location(s) · Novartis Pharmaceuticals · NCT06751238Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07243782Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adul
Phase N/A · 16 location(s) · Novartis Pharmaceuticals · NCT07543419A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Se
Phase N/A · 2 location(s) · The Affiliated Nanjing Drum Tower Hospital of Nanjing Univer · NCT06987292Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasono
Phase N/A · 2 location(s) · Nanjing Medical University · NCT06730334Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practic
Phase N/A · 4 location(s) · Novartis Pharmaceuticals · NCT06785779Secukinumab Open Label Roll-over Extension Protocol
Phase 4 · 167 location(s) · Novartis Pharmaceuticals · NCT04638647A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Phase 4 · 3 location(s) · Tongji Hospital · NCT05303285Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Phase N/A · 1 location(s) · Peking Union Medical College · NCT06926192A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Sev
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06707246Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Phase 4 · 7 location(s) · Novartis Pharmaceuticals · NCT07489573Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Phase N/A · 2 location(s) · Novartis Pharmaceuticals · NCT06905288
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.